Having trouble viewing this email? View in your browser.

A brief summary of key learnings on COVID-19 risk, in case you missed the
live events.
  Infectious disease experts from the UK and France, led by our ESCMID-appointed
chair, explored the continuing importance of identifying patients who remain at high
risk of severe COVID-19 outcomes, and the need for ongoing and adaptive protective
strategies to serve this population.

Yoav Keynan,

ESCMID-appointed chairperson
University of Manitoba,
Manitoba, Canada

Paul Loubet,

CHU Carémeau &
Montpellier University,
Nîmes, France

Key take-home points:
  • COVID-19 hospitalisations and deaths remain disproportionately high for immunocompromised individuals, despite receiving multiple vaccine doses
  • Long-acting antibodies can provide protection against COVID-19 in patients with immunocompromising conditions who do not respond well to vaccination
  • There is a need to expedite the development of new long-acting antibodies due to the evolving nature of SARS-CoV-2
  Roger Paredes, MD, PhD
Head of Department of
Infectious Diseases,
Hospital Germans Trias,
Barcelona, Spain
This session examined patient populations and characteristics associated with a heightened risk
of severe COVID-19 outcomes.
Key take-home points:
  • Immunocompromised individuals have an impaired immune response to vaccination compared with the general population due either to the mechanism of their condition or immunosuppressive therapies they require to manage their condition
  • Therefore, they remain at greater risk of COVID-19 hospitalisation and death, and incur significantly higher healthcare costs than the general population
  • Additional preventative measures such as monoclonal antibodies are needed to protect this vulnerable population from severe COVID-19 outcomes

These were non-promotional sessions organised and funded by AstraZeneca.

The information displayed during the meeting is exclusively for healthcare professionals empowered to prescribe or dispense medicinal products.

Please do not distribute in media, supporting materials or communication channels aimed at the
general public.

La información mostrada durante la reunión está dirigida exclusivamente a Profesionales Sanitarios facultados para prescribir o dispensar medicamentos. Por favor no distribuir en medios, soportes o canales de comunicación dirigidos a público general.

Vault ID: Z4-64357; Date of approval: April 2024.

©2024 AstraZeneca Global UK. 1 Francis Crick Avenue, Cambridge,
Cambridgeshire CB2 0RE, United Kingdom.

All rights reserved.

You have received this email as a contact of ESCMID or one of its affiliated societies.
You can unsubscribe here.